The global dengue vaccine market is thriving on the back of growing concern for dengue diseases as well as the clinical advancements observed in the development of vaccines for dengue. A clinical process of any pharmaceutical product undergoes various phases. With the advancement in each phase, the effectiveness of the drug is also increased, which contributes to the greater adoption of the drug around the world. Moreover, advancements observed in the development of dengue vaccine for several age groups is also anticipated to raise the demand for greater adoption of the drug by nations worldwide, and in turn influence the growth of the global dengue vaccine market. The global dengue vaccine market is anticipated to cross a value of around USD 1100.0 million by the end of 2027 with a CAGR of around 22% during the forecast period 2019-2027.
The global dengue vaccine market is segmented by regions into North America, Latin America, Europe, Asia Pacific and Middle East and Africa. Among these regions, the market of Asia Pacific dengue vaccine is driven majorly by China and India, where China is anticipated to hold the largest market share of around 30% share in the year 2027. Several outbreaks of dengue fever observed in the region over the years on the back of the region having a tropical environment, has raised the necessity of the government to increasingly focus on acquiring dengue vaccines in large quantity to address the massive population, which is majorly dominated by the two nations around the globe.
Further, Brazil, Mexico and Rest of Latin America are the prominent countries that are driving the growth of the Latin America dengue vaccine market. The Latin America region also has a tropical environment which is a favorable environment for the growth of the dengue disease. CLICK TO DOWNLOAD SAMPLE REPORT
The study further incorporates Y-O-Y Growth, demand & supply and forecast future opportunity in North America (United States, Canada), Latin America (Brazil, Mexico, Argentina, Rest of LATAM), Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX [Belgium, Netherlands, Luxembourg], NORDIC [Norway, Denmark, Sweden, Finland], Poland, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).
The global dengue vaccine market has been segmented on the basis of age group into <6 years, 6-12 years and >12 years. >12 years segment is anticipated to hold the largest market share of around 54% in the year 2027 in the global dengue vaccine market. Additionally, >12 years segment is anticipated to cross nearly USD 680 million by the end of 2027 by growing at a significant CAGR over the forecast period. Further, the <6 years segment is estimated to grow with the highest CAGR of around 22% over the forecast period.
The global dengue vaccine market is segmented by end user into hospital, clinics, government establishments, private establishments, ambulatory surgical centers and others. The clinics segment registered a significant market share along with a value of around USD 48 million in the year 2018. Clinics are the healthcare facilities which primarily focuses on the care of outpatients. Operated and managed both in private and in public sectors, clinics usually cover the primary healthcare needs of populations in the local communities. On the other hand, the hospital segment is anticipated to grow with a CAGR of around 22% during the forecast period. A hospital is a healthcare institution that provides treatment to patients with a specialized team or medical and nursing staffs. Hospitals are also equipped with medical equipment that are used to treat the patients.
According to the estimations of the World Health Organization (WHO), around 100-400 million dengue infections occur each year and that half of the world’s population is now at risk. Further, it also stated that over the last two decades, the number of dengue cases reported to the organization has increased over fifteen-fold, reaching up to 3,312,040 numbers in the year 2015.
The alarming increase in the number of dengue cases around the world is a major concern for individuals as well as the government of the nations. Moreover, due to the unavailability of the vaccine for the disease during its outbreak, several numbers of cases have been self-managed resulting in the actual number of dengue cases being under-reported. Apparently, several developed and under-developed nations around the globe are also prone to this disease on the back of unplanned and uncontrolled urbanization, poor management and others. The increasing concern for the spread of dengue virus around the world along with huge government funding for the manufacturing of the dengue vaccine, which led to greater affordability of the vaccine, are some of the factors anticipated to drive the growth of the global dengue vaccine market.
Lack of awareness of the dengue vaccine as well as for the availability of the vaccine is anticipated to hamper the growth of the global dengue vaccine market.
Some of the affluent industry leaders in the global dengue vaccine market are Merck & Co., Inc., Sanofi, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited and Institut Pasteur. Moreover, numerous players are also increasingly investing on research and development activities for the launch of advanced form of dengue vaccines.
FREQUENTLY ASKED QUESTIONS
Increasing incidences of dengue fever worldwide along with the need to vaccinate the infected individuals are some of the major factors that are driving the growth of the market.
The market is anticipated to attain a CAGR of around 22% over the forecast period, i.e. 2019-2027.
The market in Latin America is anticipated to provide more business opportunities in the future.
The major players in the global dengue vaccine market are Merck & Co., Inc., Sanofi, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited and Institut Pasteur.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
The market is majorly segmented by age group, by end user and by region.
The >12 years segment, which is a sub-segment of the age group segment, is anticipated to hold the largest market share of around 54% in the year 2027.
Lack of awareness for the availability of dengue vaccines is one of the major factors anticipated to act as a barrier towards the growth of the global dengue vaccine market.
Global Dengue Market
Chapter 1 Preface
1.1 Report Description
1.1.1 Report Introduction
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Market Segmentation
1.4 Research Methodology
1.4.1 Phase I – Secondary Research
1.4.2 Phase II – Primary Research
1.4.3 Phase III – Expert Panel Review
1.4.5 Approach Adopted
22.214.171.124 Bottom-Up Approach
126.96.36.199 Top down Approach
1.4.6 Data Triangulation
1.5 Research Assumptions
1.6 Data Sources
Chapter 2 Executive Summary
Chapter 3 Pipeline Analysis Of Dengue Vaccines
Chapter 4 Epidemiology Outlook Of Dengue Vaccines
Chapter 5 Market Dynamics
5.1 Market Drivers
5.1.1 Rising Cases of Dengue
5.1.2 Affordability of Vaccine
5.2 Market Restraints
5.2.1 Lack of awareness
5.3.1 Clinical Development of Vaccines
Chapter 6 Global Dengue Vaccine Market Analysis, by Demography
6.2 Below 5 years
6.3 5-10 years
6.4 Above 10 years
Chapter 7 Global Dengue Vaccine Market Analysis, By End- User
7.4 Ambulatory Surgical Centers
7.5 Government/Private Institutes
Chapter 8 Global Dengue Vaccine Market Analysis
Chapter 9 North America Dengue Vaccine Market Analysis
Chapter 10 Europe Dengue Vaccine Market Analysis
Chapter 11 Asia Pacific Dengue Vaccine Market Analysis
Chapter 12 Latin America Dengue Vaccine Market Analysis
12.1.1 Latin America
Chapter 13 Middle East & Africa Dengue Vaccine Market Analysis
Chapter 14 Company Profiles
14.2 Merck & Co., Inc.
14.3 Institut Pasteur
14.4 Takeda Pharmaceutical Company Limited
14.5 GlaxoSmithKline Plc
Chapter 15 Global Strategy of The Companies
15.2 Dengue vaccine candidates currently in clinical trials
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization